2000
DOI: 10.1053/jhep.2000.9142
|View full text |Cite
|
Sign up to set email alerts
|

Common and epithelioid variants of hepatic angiomyolipoma exhibit clonal growth and share a distinctive immunophenotype

Abstract: In contrast to the common renal angiomyolipoma (AML), 1 AML of the liver is very rare and has been recognized only since 1976. 2 Liver AML are usually unifocal tumors without the background of tuberous sclerosis (TSC). Until recently, AML was generally thought to be a hamartoma, composed of several tissue components. Renal AML have already been proven to be monoclonal neoplasms. 3,4 Loss of heterozygosity in the region of the tuberous sclerosis genes TSC1 (9q24) or TSC2 (16p13.3) has been shown in AML and seve… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1

Citation Types

4
36
1

Year Published

2001
2001
2016
2016

Publication Types

Select...
5
2

Relationship

1
6

Authors

Journals

citations
Cited by 73 publications
(41 citation statements)
references
References 11 publications
4
36
1
Order By: Relevance
“…Immunohistochemistry (Fig. 4) was consistent with marker profiles established in previous studies and allowed the definitive diagnosis of AML [13,14].…”
Section: Resultssupporting
confidence: 83%
See 3 more Smart Citations
“…Immunohistochemistry (Fig. 4) was consistent with marker profiles established in previous studies and allowed the definitive diagnosis of AML [13,14].…”
Section: Resultssupporting
confidence: 83%
“…Immunohistochemistry was performed on serial sections with several different antibodies using the alkaline-phosphatase-anti-alkalinephosphatase (APAAP) method. In agreement with marker profiles of other studies, the diagnosis was based on the positive staining of AML with the melanocytic markers HMB-45 (Dako, Denmark) and CD 63(NKI-C-3; Enzo, USA) [13,14,15], as well as the negative staining with the pankeratin markers KL 1 (Immunotech, France) and AE1/AE3 (Dako, Denmark) [13,15]. Kl-67 (MIB-1; Novocastra, UK), a marker of the proliferative activity, ranged from < 1 to 3 % in patients 2±5 and 7 and was increased to 5 % in patient 6 [13].…”
Section: Histopathology and Immunostainingsupporting
confidence: 71%
See 2 more Smart Citations
“…, Yasuni Nakanuma 2) , Yusuke Kinugasa 3) , Etsuro Bando Division of Gastroenterological Surgery, Shizuoka Cancer Center Hospital…”
mentioning
confidence: 99%